Paige Mahaney
Known title: Chief Scientific OfficerCIK: 0002040313
Associated companies
Transaction History
| CCCC | ▲ Buy | Option Exercise | 7,050 | $0 | 2/14/2026 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 2,446 | $5K | 2/14/2026 | View on chart |
| CCCC | ▲ Buy | Grant | 240,000 | $0 | 2/13/2026 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 19,200 | $0 | 10/28/2025 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 5,644 | $15K | 10/28/2025 | View on chart |
| CCCC | ▲ Buy | Grant | 28,200 | $0 | 2/14/2025 | View on chart |
| CCCC | ▲ Buy | Grant | 76,800 | $0 | 10/28/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials
C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials. C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.